.png){kind=small}
.png)
.png)
.png)
.png)
23 hours ago
5
ARTICLE AD BOX
As per its policy, the start-ups will be charged a maximum of 5% over the actual costs while companies may be charged up to 15% over the cost. (Image Source: Canva)
From active pharmaceutical agents for making key medicines to enzymes needed for developing biofuels, and reagents needed for manufacturing biofertilizers — the government under its BioE3 policy plans to set up around 16 biomanufacturing hubs across the country to ensure that India starts making the components for which it is largely dependent on imports. The government has already listed 1,000 such products for which there is a need to develop indigenous manufacturing facilities, which will be put on a website soon.
There has been a push towards manufacturing within the country since Covid-19 pandemic, with government policies such as performance-linked financial incentives to drug manufacturers. The department has been somewhat successful in scaling-up manufacturing of some of the drugs, but fermentation-based products still remain a challenge for the country.
With plans of setting up large fermenters of around 500 litres or 1,000 litres, these hubs can help push the manufacturing of not just fermentation-based medicines but also other products such as biofuels. “Creating these hubs helps pool the resources; meaning start-ups and small companies do not have to make big capital investments initially,” said an official from the department, on condition of anonymity.
These biomanufacturing hubs, in addition, will also look at scaling up innovative solutions such as novel monoclonal antibody treatments, new technologies for carbon capture, or smart proteins to improve nutrition developed under the programme from proof of concept to market ready products.
The Department of Biotechnology has already supported a set up of six biofoundries — a specialised facility that helps to develop and conduct the initial tests on such novel projects — at National Agri-Food and Bio-manufacturing Institute (NABI), Mohali (for sustainable food and nutrition), Tata Memorial Centre (for new drugs), International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi (for synthetic biology to make microbial cells for manufacturing enzymes, testing new biofuels, enhancing carbon capture efficiency), Translational Health Science and Technology Institute (THSTI), Faridabad (for monoclonal antibody therapies), Institute of Pesticide Formulation Technology (IPFT), Gurugram (for biopesticides), and National Centre For Cell Science (NCCS), Pune (for enzymes and metabolites).
“Once a proof of concept has been developed and tested at the biofoundries, it can be taken for manufacturing at these biomanufacturing hubs,” the official added.
Explained
BioE3 policy push
With the biomanufacturing hubs under the programme, critical ingredients for medicines, reagents needed for various products such as biofuels, bioproteins, and other chemicals for which India depends on imports, will be manufactured within the country. The Department of Biotechnology has undertaken a survey to finalise a list of 1,000 such products, which start-ups and companies may develop processes to manufacture within the country.
The biomanufacturing hubs will be set up in research institutes, private companies that specialise in a particular form of manufacturing, or near existing knowledge hubs for specific industries.
Story continues below this ad
The facilities can be accessed by government and private research institutes, universities, and colleges, along with start-ups and other companies. While the private companies will be charged, mainly to cover the cost of consumables, human resources, and other overhead charges.
As per its policy, the start-ups will be charged a maximum of 5% over the actual costs while companies may be charged up to 15% over the cost. The policy also states that the facility will not claim any intellectual property rights.
Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government’s management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country’s space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University’s Dart Centre. Dutt has a Bachelor’s Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More
Stay updated with the latest - Click here to follow us on Instagram
© The Indian Express Pvt Ltd
English (US) ·